Trial Profile
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2021
Price :
$35
*
At a glance
- Drugs Bermekimab (Primary)
- Indications Pyoderma gangrenosum
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; XBiotech
- 23 Jan 2017 Status changed from recruiting to completed.
- 22 Dec 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
- 22 Dec 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.